Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00291694 · ClinicalTrials.gov registry record · Phase 2
Protocol for Women at Increased Risk of Developing Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by Carol Fabian, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT00291694: Completed Phase 2 study of Breast Cancer, sponsored by Carol Fabian, MD.
NCT00291694 is a Phase 2 study of Breast Cancer that has completed, run by Carol Fabian, MD. The registered enrollment target is 72 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00291694, a Phase 2 study of Breast Cancer, has completed, sponsored by Carol Fabian, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the effects of twelve months of celecoxib administration by evaluating breast tissue needle aspirations, to determine if cell growth can be slowed.
Primary Outcome
Immunocytochemical staining of breast epithelial cells. Positive cells reflect proliferative activity.
Conditions Studied
Interventions
- OTHER placebo
- DRUG celecoxib
Study Locations (1)
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2003-04 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
What the finished NCT00291694 record still lists
NCT00291694 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00291694 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT00291694 about?
NCT00291694 is a clinical study titled "Protocol for Women at Increased Risk of Developing Breast Cancer". To assess the effects of twelve months of celecoxib administration by evaluating breast tissue needle aspirations, to determine if cell growth can be slowed.
What is the current status of trial NCT00291694?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2003-04. Estimated completion is 2009-12.
What conditions does trial NCT00291694 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00291694?
The interventions under investigation include: placebo (OTHER), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00291694?
This trial is sponsored by Carol Fabian, MD, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00291694 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00291694's enrollment target sits among peer trials
72 685th of 1224 higher than 533 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia